Svetlana Lucas's most recent trade in Jasper Therapeutics Inc was a trade of 20,000 Voting Common Stock done at an average price of $2.4 . Disclosure was reported to the exchange on Sept. 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jasper Therapeutics Inc | Svetlana Lucas | Director | Purchase of securities on an exchange or from another person at price $ 2.43 per share. | 22 Sep 2025 | 20,000 | 20,000 | - | 2.4 | 48,600 | Voting Common Stock |
| Jasper Therapeutics Inc | Svetlana Lucas | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Sep 2025 | 20,000 | 20,000 | - | - | Common Stock Warrant (right to buy) | |
| Jasper Therapeutics Inc | Svetlana Lucas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2025 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Svetlana Lucas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Jasper Therapeutics Inc | Svetlana Lucas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Svetlana Lucas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Svetlana Lucas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Svetlana Lucas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 6,000 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Svetlana Lucas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Svetlana Lucas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units |